Loading...
Market
Number of Gordian Bio Therapies in Clinical Trials by 2025
4
Resolution / Starting Odds
None • 20%
1-2 • 20%
3-4 • 20%
5-6 • 20%
7 or more • 20%
Clinical trial registries or official Gordian Bio communications
Story
Gordian Bio Unveils $60M Platform for Age-Related Disease Therapies
Apr 28, 2024, 03:23 PM
Gordian Bio, co-founded by Martin Jensen and Leport five years ago, has officially launched its innovative platform designed to accelerate the development of therapies for age-related diseases. The biotech startup, which unveiled its platform yesterday, has raised $60 million to support its high-throughput in vivo screening platform. This platform allows for the simultaneous testing of hundreds of gene therapies in animal models that closely mirror human biology. The company aims to produce more effective therapies more quickly and cost-effectively while using fewer animals.
View original story
Similar markets
None • 25%
1-2 • 25%
3-5 • 25%
More than 5 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
1-2 diseases • 33%
3-4 diseases • 33%
5 or more diseases • 33%
0-5 trials • 33%
6-10 trials • 33%
More than 10 trials • 34%
More than 3 • 25%
3 • 25%
2 • 25%
1 or none • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
Under 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
0 partnerships • 25%
1-2 partnerships • 25%
3-5 partnerships • 25%
More than 5 partnerships • 25%
None • 25%
1-2 partnerships • 25%
3-4 partnerships • 25%
More than 4 • 25%
10-20 • 33%
21-30 • 33%
31+ • 34%